GO
Loading...

Actavis Inc

More

  • FDA denies approval for Actavis hypertension treatment Wednesday, 24 Dec 2014 | 2:07 PM ET

    Dec 24- Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan. Actavis did not give any further details on the contents of the letter. In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension,...

  • Taser and Walgreen are big market movers Wednesday, 24 Dec 2014 | 1:37 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. Novo Nordisk AS, up 95 cents to $43.67. Walgreen Co., up 16 cents to $76.67.

  • *Initial jobless claims fall for fourth straight week. *Equity markets close at 1 p.m. in holiday-shortened session. NEW YORK, Dec 24- U.S. stocks edged higher on Wednesday, with the Dow and S&P 500 at records and on track for a sixth straight daily advance as biotech stocks rallied and data pointed to improving economic conditions.

  • NEW YORK, Dec 24- U.S. stocks were set for a modestly higher open on Wednesday on the heels of a five-day winning streak that pushed the Dow and S&P 500 to new closing records and on the latest piece of economic data indicating the economy is strengthening. "Economic data has been consistently positive," said Peter Kenny, chief market strategist at Clearpool Group in...

  • Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. Memantine is the active ingredient in Actavis' Namenda, while donepezil is the active ingredient in Pfizer Inc's Aricept. Dublin, Ireland- based Actavis said it expects to launch Namzaric in...

  • Actavis, Adamas win FDA approval for Alzheimer's drug Wednesday, 24 Dec 2014 | 8:20 AM ET

    Dec 24- The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc.. The drug, Namzaric, is designed to treat moderate-to-severe dementia in Alzheimer's patients who are stabilized with other drugs. Namzaric combines two ingredients in drugs often...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 19- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Zerbaxa is the fourth new antibacterial drug approved by the FDA this year. The agency approved Actavis Plc's Dalvance in...

  • Spain's Almirall gains on report of Actavis interest Friday, 19 Dec 2014 | 12:29 PM ET

    Dec 19- Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis. Almirall played down the report, saying in a regulatory filing that "the news is untrue." Almirall, with a market value of 2.3 billion euros, recently sold its respiratory business to AstraZeneca, while Actavis is in the...

  • Dec 18- Hedge fund Paulson& Co has taken a stake in specialty pharmaceuticals company Salix Pharmaceuticals Ltd as the company recovers from inventory issues and the departure of its chief financial officer, according to people familiar with the matter. The fund has recently taken a number of large positions in healthcare companies, including Shire PLC, where...

  • Dec 17- Tetraphase Pharmaceuticals Inc said its antibiotic to treat complicated intra-abdominal infections was as effective as Merck& co Inc's ertapenem in a late-stage study. Tetraphase is also testing the drug against Johnson& Johnson's levofloxacin to treat complicated urinary tract infections in another late-stage study, the results of which are...

  • Judge halts Alzheimer's drug swap until July Monday, 15 Dec 2014 | 5:27 PM ET

    District Judge Robert Sweet told Dublin- based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 "in order to allow for an orderly transition." His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • BOSTON, Nov 26- Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.. One week after Allergan agreed to sell itself to rival Actavis Plc., Ackman wrote in his quarterly investment letter that his Pershing Square Capital Management, the Botox-maker's biggest...

  • *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures pointed to a higher open on Monday, indicating that major indexes would move further into record territory on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday,...

  • US STOCKS-Futures rise, boosted by merger activity Monday, 24 Nov 2014 | 8:14 AM ET

    *RenaissanceRe to buy Platinum for $1.9 bln. NEW YORK, Nov 24- U.S. stock index futures rose on Monday, indicating that major indexes would move further into record territory, on the back of multiple merger deals and hopes that China will take further accommodative monetary policy action. Equities closed a fifth straight week of advances Friday, with the Dow and S&P...

  • Goldman Sachs Group Inc retained its No. 1 position as M&A adviser with deals worth $877 billion, followed by JPMorgan Chase& Co with $651 billion and Citigroup Inc with $633 billion. The $66.4 billion bid for Allergan Inc by Actavis PLC this week more than doubled the total value of deals in the healthcare sector to $364 billion. Halliburton Co's plans to buy...

  • Valeant slashes stake in Allergan after losing bid Thursday, 20 Nov 2014 | 7:14 PM ET

    Nov 20- Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent from 9.7 percent, three days after Actavis Plc trumped its offer for the Botox maker. Pershing Square Capital Management informed Valeant that PS Fund 1 sold all of its 2.2 million shares in Allergan allocated to Valeant USA, Valeant said in a regulatory filing.